Thin
Amylin Analogue
Request Quote
Direct factory access to highly characterized GLP-1/GIP co-agonists, metabolic regulators, and tissue-remodeling peptide APIs. Produced under strict cGMP-grade synthesis and chromatographic purification.
Navigating the modern therapeutic peptide landscape demands deep chemical domain mastery. Merrifield’s classical solid-phase synthesis has evolved into an automated, highly orchestrated discipline involving sterically hindered couplings, non-canonical side chains, lipophilic acylations, and rigorous stereochemical integrity control.
Utilizing specialized polymer matrices—from polystyrene crosslinked with 1% divinylbenzene (DVB) to polyethylene glycol (PEG)-grafted resins (e.g., TentaGel, ChemMatrix)—ensuring ideal swelling properties in polar aprotic solvents (DMF, NMP). Acid-labile linkers like Wang, 2-Chlorotrityl chloride (CTC), and Sieber/Rink Amide govern strict C-terminal fidelity without premature racemization or cleavage.
Overcoming intra-chain on-resin beta-sheet stacking through microwave-assisted kinetic acceleration and thermal-regulated coupling cycles. High-efficiency phosphonium and uronium salts (HATU, COMU, PyBOP) paired with OxymaPure eliminate epimerization risks in difficult sequences, particularly when appending sterically congested alpha,alpha-disubstituted amino acids like 2-aminoisobutyric acid (Aib).
Global deprotection in customized cocktail matrices (TFA/TIS/EDT/H2O) followed by temperature-stabilized ether precipitation. High-resolution preparative DAC (Dynamic Axial Compression) HPLC columns purify crude crudes to pharmaceutical standards, seamlessly accompanied by acetate-for-TFA ion-exchange chromatography to protect downstream biological formulation stability.
Understanding the transparent cost breakdown behind custom peptide quotes. Peptide API pricing is driven not merely by chain length, but by raw material stoichiometric excesses, resin substitution yields, purification throughput, and regulatory documentation requirements.
| Procurement Scale | Typical Volume | Primary Cost Variables | Analytical Package Included | Estimated Lead Times | Target Tier |
|---|---|---|---|---|---|
| Pre-Clinical / Discovery | 100mg – 100g | Manual/semi-automated cycles, high excess amino acids (3-5x), rapid cycle turnover | HPLC Purity Profile, MS Confirmation, Solubility Assessment | 2 – 3 Weeks | R&D Screen |
| Process Development (GLP) | 200g – 5kg | Resin loading optimization, solvent recycling, crude purity enhancement (>75% crude) | CoA, Peptide Content, Counter-ion (TFA/Acetate), Endotoxin assay | 4 – 6 Weeks | Pilot Verification |
| Commercial Multi-Ton (cGMP) | 10kg – 500kg+ | Stoichiometric optimization (1.2-1.5x excess), continuous-flow steps, automated DAC HPLC | Full ICH Q7 Dossier, Impurity Profiling, Residual Solvents, Stability Testing | Campaign Scheduled | Commercial API |
Modern therapeutics (Tirzepatide, Retatrutide, Cargrilintide) integrate specialized side-chain architectures, such as di-tert-butyl 18-octadecanedioate (C20 diacid mono-esters) conjugated via gamma-Glu-2xOEG linkers. The custom synthesis of these protected building blocks contributes up to 40% of early-stage raw material investment.
Prep-HPLC stationary phase life, acetonitrile consumption, and diastereomeric impurity removal dictate downstream costs. Achieving ≥99.0% chromatographic purity for a 39-amino-acid chain with 0.1% single-impurity caps requires optimized buffer gradient engineering and low-load fractions recovery.
Standard solid-phase cleavage utilizes trifluoroacetic acid (TFA), yielding residual TFA salts toxic to human cells. Converting the API to an acetate or hydrochloride salt form requires specialized ion-exchange columns or acetate-buffered reverse-phase diafiltration, which is factored into premium clinical quotes.
How Hangzhou Thinheal Pharma-Tech combines localized upstream raw material security, intelligent synthesis automation, and green manufacturing metrics to mitigate global supply volatility.
China produces over 70% of the world's standard Fmoc-protected amino acids, coupling agents (HBTU, HATU, EDC), and base resins. Thinheal’s Hangzhou manufacturing campus sits directly downstream of this robust petrochemical and fine-chemical ecosystem, protecting project schedules from international raw material shortfalls and tariffs.
Operating continuous and batch solid-phase synthesis vessels ranging up to 3,000L and 5,000L capacity. Automated solvent washing manifolds, sensor-controlled coupling reaction temperatures, and automated in-line UV deprotection monitoring eliminate manual technician variance across commercial manufacturing campaigns.
Traditional SPPS generates substantial chemical waste via DMF and DCM consumption. Thinheal has engineered closed-loop distillation cycles recovering >85% of process DMF and acetonitrile, drastically lowering Process Mass Intensity (PMI) values and ensuring full environmental compliance with modern ESG benchmarks.
Equipped with Agilent and Waters ultra-performance liquid chromatography (UPLC), quadrupole time-of-flight mass spectrometers (Q-TOF MS), and ICP-MS for heavy metals. Full chromatographic data packages accompany each batch to ensure regulatory audit readiness.
Industrial-grade cleanroom freeze-dryers featuring nitrogen blanket sealing and vacuum shelf-temperature programming. Lyophilized powders are strictly verified for specific surface moisture, cake integrity, and reconstitution kinetics.
Pioneering the hybrid combination of liquid-phase peptide synthesis (LPPS) with SPPS fragment condensation. By pre-assembling complex lipophilic fragments in solution and coupling them to solid-phase resin backbones, overall cycle times are shortened by 45%.
From blockbuster GLP-1 analogues transforming metabolic disease management to neuro-protective compounds and cosmeceutical matrix-builders, our synthesis platforms are tailor-engineered to overcome distinct biochemical hurdles.
Scalable synthesis routes for Semaglutide, Tirzepatide, and Retatrutide. Overcoming secondary structure folding issues during on-resin assembly of long incretin sequences through specialized backbone protection.
Purity-stabilized GLP-2 analogues like Teduglutide for Short Bowel Syndrome (SBS). Robust controls against aspartimide formation and deamidation during acidic cleavage and purification.
High-potency neuro-regulators like Selank and Semax. Focused on strict peptide content determinations, zero microbial endotoxin thresholds, and ultra-low water content for extended cold-chain stability.
High-volume cosmetic peptides including GHK-Cu, Argireline, and Matrixyl series. Guaranteed batch reproducibility, absent trace copper leaching, and optimal transdermal formulation compatibility.
Regulatory alignment is non-negotiable for clinical sponsors and commercial brands. Our dedicated quality assurance teams manage international compliance files to accelerate your IND, NDA, and ANDA submissions.
Providing comprehensive Drug Master Files (Type II DMF) with fully documented impurity characterization profiles, process validation protocols, and degradation pathway studies in line with ICH Q3A/Q3B/Q6A guidance.
Peptide APIs undergo calibrated dry-ice or -20°C temperature-monitored international transport via specialized courier routes. Real-time data loggers verify cargo integrity from our Hangzhou plant to destinations across the Americas, Europe, and Asia.
Technical and commercial desks operating in multiple languages (English, Chinese, Russian) directly handle customs clearance, export declarations, and project milestone updates to support buyers in their respective time zones.
Explore specialized melanocortin agonists, selective cellular repair factors, next-generation incretin mimetics, and small-molecule GLP-1 receptor modulators. Available from pilot grams to multi-kilogram commercial lots.
Detailed chemical, analytical, and operational answers addressing the core questions of pharmaceutical sourcing managers and peptide scientists.
Pricing is calculated through a multi-factor formula: the sequence length, difficult-to-couple residues (such as consecutive hydrophobic or beta-branched valine, isoleucine, or Aib residues), choice of solid support resin (CTC vs. Wang vs. Rink Amide), stoichiometry of amino acid excess required, target purity threshold (≥95% vs ≥98% vs ≥99.5%), and the desired counter-ion (Trifluoroacetate vs. Acetate exchange). Multi-gram and multi-kilogram batches benefit from automated scaling economies.
HPLC Purity represents the percentage of the target peptide peak relative to all UV-absorbing peptide-related substances in the chromatogram at 214nm or 220nm. Net Peptide Content accounts for the actual weight of the peptide molecules relative to moisture, residual counter-ions (TFA, acetate), and residual solvents. A peptide can exhibit 99% HPLC purity while possessing an 82% net peptide content—an essential distinction for accurate therapeutic dosing.
We implement automated real-time UV monitoring of the Fmoc deprotection stream to verify complete piperidine-mediated dibenzofulvene adduct release. For sterically challenging couplings, we use high-energy activation cocktails (HATU/COMU with OxymaPure) alongside acetic anhydride capping steps after each coupling cycle to permanently terminate unreacted amines, preventing near-identical deletion impurities that complicate downstream prep-HPLC.
Yes. Our multi-ton synthesis base in Hangzhou specializes in complex branched incretin analogues. We have optimized orthogonal side-chain deprotection protocols (e.g., Lys(Alloc) or Lys(Mtt)) to allow site-selective attachment of the octadecanedioic acid or eicosanedioic acid lipid moieties via hydrophilic AEEA/gamma-Glu spacers while the peptide backbone remains protected on the solid support.
Standard deliveries include a comprehensive batch-specific Certificate of Analysis (CoA) containing analytical RP-HPLC traces, High-Resolution Electrospray Ionization Mass Spectrometry (HRMS/ESI-MS), Karl Fischer water titration, and solubility data. For clinical CDMO clients, we supply complete impurity qualification profiles, residual solvent testing (GC-MS), bacterial endotoxin reports (LAL test), and Drug Master File (DMF) filing support.
Lyophilized peptides are packaged in high-barrier amber borosilicate vials purged with dry inert argon or nitrogen gas to prevent moisture uptake and atmospheric oxidation. Shipments to North America, Europe, and Asia are dispatched via priority cold-chain express services with temperature-controlled insulated packaging (-20°C dry ice or 2-8°C ice packs) and accompanying continuous temperature logging devices.
Connect directly with Hangzhou Thinheal Pharma-Tech’s peptide chemistry and regulatory specialists. Submit your sequence, target purity, batch size, and salt requirements for a confidential technical evaluation and transparent commercial quote.